PASSION FOR PRECISION.

ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.

Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer.

ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

For more information please visit: www.itm-radiopharma.com.


Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines

ITM Isotope Technologies Munich SE

Our sincerest thanks to everyone who took the time to stop by and sign our 20th Anniversary card at #SNMMI24 to help raise money for the Dream Foundation.

Together we were able to make a patient’s dream come true. 

#ITM #dreamfoundation #charity #grateful

Please join us this evening for the ITM Dinner Symposium “𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙉𝙚𝙚𝙙𝙨 𝘿𝙧𝙞𝙫𝙞𝙣𝙜 𝙍𝙖𝙙𝙞𝙤𝙥𝙝𝙖𝙧𝙢𝙖𝙘𝙚𝙪𝙩𝙞𝙘𝙖𝙡 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙖𝙣𝙙 𝙎𝙘𝙖𝙡𝙖𝙗𝙡𝙚 𝙎𝙤𝙡𝙪𝙩𝙞𝙤𝙣𝙨” at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. 

Our distinguished panel of speakers will provide valuable insights into the well-established clinical utility of beta-emitting Lu-177 therapies and the potential of alpha-emitting Ac-225 and Auger-emitting Tb-161. They will also examine ongoing research that supports the development of new radiopharmaceuticals and how a sustainable supply of isotopes is being established to address the rapidly growing demands of clinicians and researchers worldwide.

📅 June 9, 2024, at 6:30pm – 7:30pm 

To learn more about this exciting program visit https://lnkd.in/ePcxZGhr

#ITM #theranostics #nuclearmedicine #radiopharmaceuticals #radioisotopes

Join the ITM Team in Booth #1317 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to celebrate 20 years of our shared dedication to improving clinical outcomes and quality of life for patients and help us make patients’ dreams come true!

For everyone that stops by and signs our anniversary card, ITM will donate to the Dream Foundation in support of their mission of providing patients and their families the opportunity to fulfill their dreams.

ITM is proud to partner with the Dream Foundation for our shared goal of improving the quality of life for patients. If you can’t stop by but wish to learn more about the Dream Foundation, please visit www.dreamfoundation.org.

Thank you for your continued support over the past 20 years! We look forward to celebrating with you!

#ITM #SNMMI24 #Radioisotopes #Radiopharmaceuticals #theranostics

Today we are pleased to announce a €188 million equity #investment led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority (QIA), ATHOS and Carbyne.

This new capital will enable us to achieve our next major milestones on providing cancer patients with more effective targeted treatment to improve clinical outcomes and quality of life:

💡 Advancing and expanding our targeted #radiopharmaceutical pipeline

🔬 Preparing for the potential launch of our Phase III lead candidate, #ITM-11, as it nears clinical read-out

🏭 Expanding our manufacturing capabilities for alpha- and beta-emitting #radioisotopes, including Lutetium-177 and Actinium-225.
 
Read the full announcement here: https://lnkd.in/d5pQvE_u

Exciting news: Today we are pleased to announce a major initiative with Bruce Power, Isogen, the Saugeen Ojibway Nation and ITM to double production capacity for cancer-fighting medical #isotopes. The installation of a second production line is a significant step forward in enhancing and accelerating our global production of Lutetium-177. 
 
This milestone would not have been possible without the great cooperation of all partners. 

For more details, please see the press release linked in the comment. 👇 
 
#Radiopharma #Radiopharmaceutical #Therapy

#20YearsITM – 20 years of #PassionForPeople. 🌈 
 
Today, on the 12th German Diversity Day, we celebrate the power of #diversity! 🎉 As a proud member of @Charta der Vielfalt e.V., we are committed to raising awareness of diversity in the workplace. 
 
To honor this year’s Diversity Day, we asked our employees what diversity means to them. Be inspired by some of their answers in the video below. 📸 
 
🌟 At ITM, our employees are the heart of our success. Their #passion, diversity and unique talents have played a key role in our company's achievements over the past 20 years - and will continue to drive us forward in the future. 
🌍 We are proud of our diverse workforce, which includes a variety of cultural backgrounds, age groups, gender identities, sexual orientations, life experiences and much more. Diversity in all its forms is our strength and what fuels our advancement. 
🤝 United, we’re shaping the future of ITM, committed to an inclusive work environment where everyone's voice is heard.  
 
#DDT24 #DiversityMatters

Isotopen Technologien Munchen AG is a company focused on the development and production of radiopharmaceuticals and radioisotopes for medical applications.

Isotopen Technologien Munchen AG

Hermes Arzneimittel GmbH is a pharmaceutical company specializing in the development and production of various medications and pharmaceutical products.

Hermes Arzneimittel GmbH

Navidea Biopharmaceuticals is a biotechnology company focused on precision diagnostics and radiopharmaceutical agents for oncology and other medical applications.

Navidea Biopharmaceuticals

ITM Isotope Technologies Munich SE is a biotechnology and radiopharmaceutical company focused on the development, production, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for cancer treatment. The company has established GMP manufacturing and a global supply network for innovative medical radioisotopes and generator platforms. ITM is also actively involved in the clinical development of a proprietary Precision Oncology Pipeline, including targeted treatments for various cancers.

news impact assignment basic	general
public peers	general	Jul 1, 2024 11:00 AM	ebbd32ac
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 1, 2024 12:21 PM	5cadde5f
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	4fcc77a7
crunchbase profile	general
li profile	general	Jul 1, 2024 11:00 AM	6661e166
translate crunchbase fundingrounds	general
peers	general
news basic	general	Jul 1, 2024 11:00 AM	70c9ec99
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ITM-RADIOPHARMA

ITM Isotope Technologies Munich SE